Court Opinion

ID: 4524761
Source: CourtListenerOpinion
Date Created: 2020-04-13 16:00:49.578268+00
Date Added: 2024-06-11T12:12:18.566358
License: Public Domain

UNITED STATES DISTRICT COURT
                               FOR THE DISTRICT OF COLUMBIA

 SUZANNE STILL,

                 Petitioner,

         v.
                                                            No. 17-cv-1420 (DLF)
 UNITED STATES DEPARTMENT OF
 LABOR,

                 Respondent.

                          MEMORANDUM OPINION AND ORDER

       Petitioner Suzanne Still brings this lawsuit against respondent Department of Labor

(“DOL”), challenging DOL’s final decision denying her compensation for her husband’s death

under the Energy Employees Occupational Illness Compensation Program Act, 42 U.S.C. § 7384

et seq. (the “EEOICPA”). See Dkt. 18 (Am. Pet.). Still argues that the dose reconstruction

prepared by the National Institute of Occupational Safety and Health (“NIOSH”), upon which

DOL’s decision relied, failed to comply with the methodology required by NIOSH’s own

guidance documents. See, e.g., Am. Pet. ¶ 22. Accordingly, Still contends that DOL’s decision

violates the APA and asks the Court to “set aside, vacate, modify, or reverse” that decision. Id.

at 28; see 5 U.S.C. § 706(2)(A) (reviewing courts shall “hold unlawful and set aside agency

action, findings, and conclusions found to be . . . arbitrary, capricious, an abuse of discretion, or

otherwise not in accordance with law”). Before the Court is DOL’s Motion to Dismiss under

Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6) on the ground that Still lacks standing.

See Dkt. 20 (Mot. to Dismiss).
I.     BACKGROUND

       A.      Statutory and Regulatory Background

       Congress passed the EEOICPA in 2000 to ensure that former Department of Energy

(“DOE”) workers who “performed duties uniquely related to the nuclear weapons production and

testing programs” receive “efficient, uniform, and adequate compensation for . . . radiation-

related health conditions.” 42 U.S.C. § 7384(a)(8). Under Part B of the EEOICPA, covered

employees or their eligible survivors can receive up to $150,000 of compensation for certain

covered illnesses caused by exposure to radiation at DOE facilities. See 42 U.S.C. §§ 7384l–

7384w-1.

       An individual seeking compensation and benefits under EEOICPA must file a claim with

the DOL’s Office of Workers’ Compensation Programs (“OWCP”). See Exec. Order No.

13,179, 65 Fed. Reg. 77,487 (December 7, 2000); 20 C.F.R. § 30.1. To establish eligibility for

compensation under Part B, the employee or survivor must show (1) that the employee was

diagnosed with cancer; (2) that he was a DOE employee or contractor who was diagnosed with

cancer after employment at a covered facility; and (3) that the cancer was “at least as likely as

not” related to his employment at the covered facility. 20 C.F.R. § 30.210.

       To determine whether it is “at least as likely as not” that a DOE employee’s illness was

related to his employment at a DOE facility, OWCP transfers relevant information about the

employee to NIOSH to perform a “dose reconstruction.” See 20 C.F.R. § 30.115. Dose

reconstructions are “reasonable estimates of the radiation doses received by individuals . . . for

whom there are inadequate records of radiation exposure.” Exec. Order No. 13,179, 65 Fed.

Reg. at 77,488. Based on the dose reconstruction report it receives from NIOSH, “together with

information on the cancer diagnosis and other personal information provided to DOL by the

                                                 2
claimant,” OWCP calculates the approximate likelihood that exposure to radiation at a DOE

facility caused the employee’s cancer. 42 C.F.R. § 82.4. In determining the probability of

causation, OWCP is statutorily required to use the dose reconstruction provided by NIOSH. See

42 U.S.C. § 7384n; 42 C.F.R. § 81.6. If the probability of causation is equal to or greater than

fifty percent, it is “at least as likely as not” that exposure to radiation at a DOE facility caused the

cancer, and therefore the claimant is eligible for compensation. 20 C.F.R. § 30.213.

        After determining whether the causation threshold is met, OWCP issues a recommended

decision regarding the claimant’s compensation claim. 20 C.F.R. § 30.300. A claimant may

challenge the recommended decision within sixty days by filing an objection with OWCP’s Final

Adjudication Branch (“FAB”). Id. § 30.310. FAB then issues a “final decision,” but the

claimant may request reconsideration within thirty days and the Director of the Division of

Energy Employees Occupational Illness Compensation (“DEEOIC”) can reopen the claim as a

matter of discretion. Id. §§ 30.316, 30.319, 30.320.

        B.      Still’s EEOICPA Claim

        Still’s husband was employed from January 1, 1974 until November 1, 1999 at a DOE

facility engaged in the production of nuclear weapons. Am. Pet. ¶ 2. During his life, he was

diagnosed with four skin cancers, a blood cancer, and a brain cancer; he died of the latter on

September 29, 2014. Id. ¶¶ 2, 3.

        Still filed her initial compensation claim with OWCP on October 10, 2014. Id. Ex. 2 at 1.

OWCP referred the claim to NIOSH, which issued a dose reconstruction report on December 10,

2014. See id. Based in part on this first report, OWCP denied Still’s claims in a final decision

dated December 27, 2016 and denied her request for reconsideration on May 18, 2017. Id. On

November 22, 2017, however, the Director of DEEOIC vacated OWCP’s December 27, 2016

                                                   3
final decision and its May 18, 2017 denial of reconsideration. Id. According to OWCP, the

Director vacated the decisions so that OWCP “could conduct further development of [Still’s]

survivor claim, including another referral to [NIOSH] for a rework of the prior December 10,

2014 dose reconstruction,” and to address each of the technical objections that Still had

previously raised in relation to that dose reconstruction. Id. at 1–2.

       NIOSH then compiled a draft of its reworked dose reconstruction report, which

responded to Still’s thirteen technical objections to the original dose reconstruction report, and

ultimately concluded that there was only a 33.72% chance that radiation exposure at a DOE

facility had caused her husband’s cancer. Id. at 5. NIOSH sent Still a draft of its reworked dose

reconstruction and offered her the opportunity to raise any objections to the draft report. Id. at 2.

Still declined to do so, and signed NIOSH’s Form OCAS-1, certifying that she did not have any

further information to provide to NIOSH for its use in completing the dose reconstruction. Id.

       Based on the reworked dose reconstruction, OWCP concluded that it was not “at least as

likely as not” that Still’s husband’s cancer was caused by radiation exposure at his workplace;

accordingly, on September 10, 2018, OWCP issued a recommended decision denying Still’s Part

B claim. Id. at 5. Still did not submit objections to this recommended decision. Id. at 6. On

November 19, 2018, FAB issued a final decision denying her Part B claim. Id. at 1.

       Still then submitted a request for reconsideration of the November 19, 2018 final

decision, along with her objections to that decision. Id. Ex. 3 at 1. In assessing whether to grant

Still’s request for reconsideration, FAB consulted a health physicist within the DEEOIC who

reviewed Still’s objections to the November 19 decision. Id. at 2. The health physicist

concluded that NIOSH had followed standard dose reconstruction procedures in assessing Still’s

                                                  4
claim, id. at 4, and FAB accordingly concluded that there was no basis to reconsider the decision,

id. at 5. FAB denied Still’s request for reconsideration on March 5, 2019. Id. at 1.

        C.      Procedural History

        On July 17, 2017, Still filed her original petition in this Court, listing both DOL and

NIOSH as respondents and primarily challenging NIOSH’s 2014 dose reconstruction. See Dkt. 1

(Pet.). On December 29, 2017, the parties filed a joint motion to stay the proceedings while

DOL completed its re-adjudication of Still’s claims and a joint stipulation dismissing NIOSH

from the case. See Dkt. 13 (Joint Mot. to Stay). The Court granted the motion to stay and

dismissed NIOSH without prejudice. Min. Order of Dec. 30, 2017. On April 4, 2019, the Court

lifted the stay at the parties’ request. Min. Order of Apr. 4, 2019.

        Still filed her amended petition on June 27, 2019, asking the Court to “set aside, vacate,

modify, or reverse” DOL’s November 19, 2018 decision, Am. Pet. at 28, on the ground that

NIOSH had failed to properly calculate her husband’s dose reconstruction, id. ¶ 22. Specifically,

Still contends that NIOSH’s own guidelines required it to include doses of neutrons, tritium, and

strontium in her husband’s dose reconstruction. E.g., id. ¶¶ 63, 102, 106. On July 25, 2019,

DOL filed its motion to dismiss, arguing that Still lacks standing because any injury caused by

NIOSH’s allegedly erroneous dose reconstruction would not be redressable by a Court order

against DOL, the only agency remaining in the case. Mot. to Dismiss at 10–13.

II.     LEGAL STANDARDS

        A.      Federal Rule of Civil Procedure 12(b)(1)

        Under Rule 12(b)(1), a party may move to dismiss a claim over which the court lacks

subject-matter jurisdiction. Fed. R. Civ. P. 12(b)(1). “When ruling on a Rule 12(b)(1) motion,

the court must treat the plaintiff’s factual allegations as true and afford the plaintiff the benefit of

                                                   5
all inferences that can be derived from the facts alleged.” Jeong Seon Han v. Lynch, 223 F.

Supp. 3d 95, 103 (D.D.C. 2016) (internal quotation marks and citation omitted). “Because Rule

12(b)(1) concerns a court’s ability to hear a particular claim, the court must scrutinize the

plaintiff’s allegations more closely when considering a motion to dismiss pursuant to Rule

12(b)(1) than it would under a motion to dismiss pursuant to Rule 12(b)(6).” Schmidt v. U.S.

Capitol Police Bd., 826 F. Supp. 2d 59, 65 (D.D.C. 2011). If the court determines that it lacks

jurisdiction, the court must dismiss the claim or action. Fed. R. Civ. P. 12(b)(1), 12(h)(3).

III.   ANALYSIS

       The standing requirement imposed by Article III of the Constitution “contains three

elements”: (1) the plaintiff must have suffered an “injury in fact” that is “concrete and

particularized” and “actual or imminent, not conjectural or hypothetical”; (2) there must exist “a

causal connection between the injury and the conduct complained of”; and (3) it must be “likely,

as opposed to merely speculative, that the injury will be redressed by a favorable decision.”

Lujan v. Defs. of Wildlife, 504 U.S. 555, 560–61 (1992) (internal quotation marks omitted). “The

burden of establishing these elements falls on the party invoking federal jurisdiction, and at the

pleading stage, a plaintiff must allege facts demonstrating each element.” Friends of Animals v.

Jewell, 828 F.3d 989, 992 (D.C. Cir. 2016). The plaintiff “must demonstrate standing separately

for each form of relief sought.” Friends of the Earth, Inc. v. Laidlaw Envtl. Servs. (TOC), Inc.,

528 U.S. 167, 185 (2000).

       At issue in this case is the third standing requirement: redressability. “Redressability

examines whether the relief sought, assuming that the court chooses to grant it, will likely

alleviate the particularized injury alleged by the plaintiff.” Fla. Audobon Soc’y v. Bentsen, 94

F.3d 658, 663–64 (D.C. Cir. 1996). Still’s challenge to DOL’s final decision denying her

                                                  6
EEOICPA claim is directed at the dose reconstruction prepared by NIOSH, upon which DOL

relied in reaching that decision. Still contends that NIOSH failed to adhere to its dose

reconstruction methodology guidelines when it prepared her husband’s dose reconstruction and

that DOL, and its health physicist in particular, “blindly adopt[ed]” NIOSH’s “facially flawed”

dose reconstruction report. Am. Pet. § 22; Dkt. 22 (Opp’n to Mot. to Dismiss) at 10. In her

amended petition, Still requests that the Court “set aside, vacate, modify, or reverse” DOL’s

decision and “order [DOL] to obtain a proper Dose Reconstruction from NIOSH on which to

base a just determination on [her] EEOICPA claim.” Am. Pet. at 28.

       Still’s requested relief is unlikely to redress her particularized injury. That is because her

alleged injury stems from an erroneous dose reconstruction calculated by NIOSH. But NIOSH is

no longer a party to this lawsuit. And DOL, the only remaining agency respondent, is legally

required to accept the dose reconstruction as NIOSH calculates it. See 42 C.F.R. § 81.6

(“Determining probability of causation will require the use of radiation dose information

provided to DOL by the National Institute for Occupational Safety and Health (NIOSH)

. . . .”). DOL has no authority to compel NIOSH to change its dose reconstruction. Indeed, if the

Court were to order the relief that Still seeks—either by simply setting aside DOL’s final

decision or by going further and ordering DOL to “obtain a proper Dose Reconstruction from

NIOSH,” Am. Pet. at 28—the most that DOL could do to effectuate the Court’s order is “return

the case to the district office for referral to NIOSH for such further action as may be

appropriate,” 20 C.F.R. § 30.318(a). But a referral from DOL would not likely redress an injury

that ultimately derives from a dose reconstruction calculated independently by NIOSH, and over

which NIOSH retains sole authority.

       In resisting this conclusion, Still argues that NIOSH “is not immune to criticism or

                                                 7
correction, but is likely to attempt in good faith to respond to that criticism especially if that

criticism comes from a federal court.” Opp’n to Mot. to Dismiss at 2. But to meet the

redressability requirement, Still must show that it is “likely, as opposed to merely speculative,”

that a ruling in her favor will redress the alleged harm. Lujan, 504 U.S. at 561. Still’s

predictions about NIOSH’s “good faith” and willingness to “respond to . . . criticism,” Opp’n to

Mot. to Dismiss at 2, are instead “overly speculative,” Arpaio v. Obama, 797 F.3d 11, 21 (D.C.

Cir. 2015). Indeed, the fact that NIOSH has previously responded to Still’s technical objections

to its dose reconstruction calculation, Am. Pet. Ex. 2 at 2–5, suggests that NIOSH might well

believe it has already addressed its fair share of criticisms, and regard DOL’s pleas to reconsider

accordingly. Therefore, because NIOSH is not a party to this litigation and because DOL has no

authority to force a change in NIOSH’s dose reconstruction, “it is entirely conjectural whether

the . . . activity that affects [Still] will be altered or affected by the agency activity [she] seek[s]

to achieve.” Lujan, 504 U.S. at 571.

        For these reasons, the relief Still seeks in her amended petition will not “likely alleviate

the particularized injury alleged.” Fla. Audobon Soc’y, 94 F.3d at 664. Still therefore lacks

standing, and the Court will grant DOL’s motion to dismiss. But the Court will grant Still leave

to file an amended petition and restore NIOSH as a party to this lawsuit. With both agencies

present before the Court, Still’s petition would challenge a final agency action—DOL’s decision

to deny her EEOICPA claim—that the Court could “set aside, vacate, modify, or reverse” under

the APA. See, e.g., Ergon-W.Va., Inc. v. U.S. Envtl. Prot. Agency, 896 F.3d 600, 610 (4th Cir.

2018) (vacating and remanding to EPA because its “reliance on a facially-flawed report”

prepared by DOE was “arbitrary and capricious”). At the same time, NIOSH’s presence and

participation in the lawsuit would substantially increase the likelihood that a vacatur of that

                                                    8
decision would lead NIOSH to redress any flaws in the dose reconstruction that the Court’s

ruling identified. 1 Accordingly, DOL’s motion to dismiss will be granted without prejudice, but

Still may file an amended petition adding NIOSH as a respondent. Fed. R. Civ. P. 15(a)(2).

                                                 CONCLUSION

              For the foregoing reasons, it is

              ORDERED that the respondent’s Motion to Dismiss, Dkt. 20, is GRANTED. It is

    further

              ORDERED that the plaintiff shall file a second amended petition on or before May

    15, 2020.

                                                              ________________________
                                                              DABNEY L. FRIEDRICH
Date: April 13, 2020                                          United States District Judge

1
  Nor would it pose an obstacle to redressability that Still’s claim might once again be denied on
remand—or even that NIOSH, conforming its dose reconstruction to any future adverse ruling
from the Court, might reach the same result. To the contrary, “[i]f a reviewing court agrees” that
an agency’s decision was contrary to law, “it will set aside the agency’s action and remand the
case—even though the agency (like a new jury after a mistrial) might later, in the exercise of its
lawful discretion, reach the same result for a different reason.” FEC v. Akins, 524 U.S. 11, 25
(1998).

                                                     9